This book functions as a comprehensive and authoritative reference book in blood transfusion and blood substitutes. It is a collection of the latest developments and the newest investigations, and individual chapters are written by world experts in the arena. The book begins with a historical review on the practice of transfusions as well as the components and physiology of blood. The following chapters cover various topics, including platelet substitutes, hemoglobin-based oxygen carriers, perfluorocarbon based oxygen carriers, and safety issues related to artificial hemoglobin. All…mehr
This book functions as a comprehensive and authoritative reference book in blood transfusion and blood substitutes. It is a collection of the latest developments and the newest investigations, and individual chapters are written by world experts in the arena.
The book begins with a historical review on the practice of transfusions as well as the components and physiology of blood. The following chapters cover various topics, including platelet substitutes, hemoglobin-based oxygen carriers, perfluorocarbon based oxygen carriers, and safety issues related to artificial hemoglobin. All chapters provide a bulleted highlights list to facilitate readers in mastering the main points of each individual chapter.
Blood Substitutes and Oxygen Biotherapeutics is an invaluable reference book for perioperative care providers, hematologists, anesthesiologists, surgeons, obstetricians and gynecologists.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Henry Liu M.D Pennsylvania State University College of Medicine Milton S. Hershey Medical Center Anesthesiology & Perioperative Medicine Hershey, Pennsylvania 17033 USA Dr. Alan David Kaye, MD, PhD, DABA, DABPM, DABIPP, FASA Vice-Chancellor of Academic Affairs, Chief Academic Officer, and Provost, Tenured Professor of Anesthesiology and Pharmacology, Toxicology, and Neurosciences, Pain Fellowship Program Director, LSU School of Medicine, 1501 Kings Hwy, Shreveport, LA 71103 Jonathan S. Jahr David Geffen school of Medicine at UCLA Los Angeles California
Inhaltsangabe
ATP and Oxygen: the Energy Economy of the Cell.- Physiological Functions of Blood.- Hemoglobin: Physiology and Hemoglobinopathy.- The Global Burden of Anemia.- Blood Component Therapy: the History, Efficacy, and Adverse Effects in Clinical Practice.- Allogeneic Blood Transfusion: Complications and Side Effects.- The real-time effects of artificial blood substitutes on the microcirculation.- Vascular endothelium and nitric oxide.- A Brief History of Development of Nanobiotechnology-based Blood Substitutes.- Classification of Blood Substitutes.- Hemoglobin-based Oxygen Carriers.- Complications of HBOCs including clinical safety issues.- Free Hemoglobin Toxicity.- Nanotechnology-based oxygen and drug carriers.- Perfluorocarbon-based Oxygen Carriers.- Platelet Substitutes.- Plasma Substitutes.- Novel nanobiotherapeutic based blood substitutes.- Paradigm Shift.- Hemoglobin-Based Blood Substitute.- Hemoglobin vesicles as artificial red cells.- Low Volume Resuscitation Agents in Prehospital Medicine.- ErythroMer: Bio-Inspired Artificial Red Blood Cell.- OxyVita-Erythrocruorin.- HemAssist: History, clinical trials.- Development of Recombinant Hemoglobin.- Hemolink-PolyHeme.- Safety and Tolerability Study -in Stable Adult Patients with Sickle Cell disease.- Oxygent-Sanguinate.- M101, the Hemoglobin from the Sea-Hemopure: clinical trials and current status.- Perftoran: History-Oxycyte-Hemoximer.- Transplantation.- Hemorrhagic Shock: HBOCs in Trauma.- Use of Oxygen.- Regulatory Update.
ATP and Oxygen: the Energy Economy of the Cell.- Physiological Functions of Blood.- Hemoglobin: Physiology and Hemoglobinopathy.- The Global Burden of Anemia.- Blood Component Therapy: the History, Efficacy, and Adverse Effects in Clinical Practice.- Allogeneic Blood Transfusion: Complications and Side Effects.- The real-time effects of artificial blood substitutes on the microcirculation.- Vascular endothelium and nitric oxide.- A Brief History of Development of Nanobiotechnology-based Blood Substitutes.- Classification of Blood Substitutes.- Hemoglobin-based Oxygen Carriers.- Complications of HBOCs including clinical safety issues.- Free Hemoglobin Toxicity.- Nanotechnology-based oxygen and drug carriers.- Perfluorocarbon-based Oxygen Carriers.- Platelet Substitutes.- Plasma Substitutes.- Novel nanobiotherapeutic based blood substitutes.- Paradigm Shift.- Hemoglobin-Based Blood Substitute.- Hemoglobin vesicles as artificial red cells.- Low Volume Resuscitation Agents in Prehospital Medicine.- ErythroMer: Bio-Inspired Artificial Red Blood Cell.- OxyVita-Erythrocruorin.- HemAssist: History, clinical trials.- Development of Recombinant Hemoglobin.- Hemolink-PolyHeme.- Safety and Tolerability Study -in Stable Adult Patients with Sickle Cell disease.- Oxygent-Sanguinate.- M101, the Hemoglobin from the Sea-Hemopure: clinical trials and current status.- Perftoran: History-Oxycyte-Hemoximer.- Transplantation.- Hemorrhagic Shock: HBOCs in Trauma.- Use of Oxygen.- Regulatory Update.
ATP and Oxygen: the Energy Economy of the Cell.- Physiological Functions of Blood.- Hemoglobin: Physiology and Hemoglobinopathy.- The Global Burden of Anemia.- Blood Component Therapy: the History, Efficacy, and Adverse Effects in Clinical Practice.- Allogeneic Blood Transfusion: Complications and Side Effects.- The real-time effects of artificial blood substitutes on the microcirculation.- Vascular endothelium and nitric oxide.- A Brief History of Development of Nanobiotechnology-based Blood Substitutes.- Classification of Blood Substitutes.- Hemoglobin-based Oxygen Carriers.- Complications of HBOCs including clinical safety issues.- Free Hemoglobin Toxicity.- Nanotechnology-based oxygen and drug carriers.- Perfluorocarbon-based Oxygen Carriers.- Platelet Substitutes.- Plasma Substitutes.- Novel nanobiotherapeutic based blood substitutes.- Paradigm Shift.- Hemoglobin-Based Blood Substitute.- Hemoglobin vesicles as artificial red cells.- Low Volume Resuscitation Agents in Prehospital Medicine.- ErythroMer: Bio-Inspired Artificial Red Blood Cell.- OxyVita-Erythrocruorin.- HemAssist: History, clinical trials.- Development of Recombinant Hemoglobin.- Hemolink-PolyHeme.- Safety and Tolerability Study -in Stable Adult Patients with Sickle Cell disease.- Oxygent-Sanguinate.- M101, the Hemoglobin from the Sea-Hemopure: clinical trials and current status.- Perftoran: History-Oxycyte-Hemoximer.- Transplantation.- Hemorrhagic Shock: HBOCs in Trauma.- Use of Oxygen.- Regulatory Update.
ATP and Oxygen: the Energy Economy of the Cell.- Physiological Functions of Blood.- Hemoglobin: Physiology and Hemoglobinopathy.- The Global Burden of Anemia.- Blood Component Therapy: the History, Efficacy, and Adverse Effects in Clinical Practice.- Allogeneic Blood Transfusion: Complications and Side Effects.- The real-time effects of artificial blood substitutes on the microcirculation.- Vascular endothelium and nitric oxide.- A Brief History of Development of Nanobiotechnology-based Blood Substitutes.- Classification of Blood Substitutes.- Hemoglobin-based Oxygen Carriers.- Complications of HBOCs including clinical safety issues.- Free Hemoglobin Toxicity.- Nanotechnology-based oxygen and drug carriers.- Perfluorocarbon-based Oxygen Carriers.- Platelet Substitutes.- Plasma Substitutes.- Novel nanobiotherapeutic based blood substitutes.- Paradigm Shift.- Hemoglobin-Based Blood Substitute.- Hemoglobin vesicles as artificial red cells.- Low Volume Resuscitation Agents in Prehospital Medicine.- ErythroMer: Bio-Inspired Artificial Red Blood Cell.- OxyVita-Erythrocruorin.- HemAssist: History, clinical trials.- Development of Recombinant Hemoglobin.- Hemolink-PolyHeme.- Safety and Tolerability Study -in Stable Adult Patients with Sickle Cell disease.- Oxygent-Sanguinate.- M101, the Hemoglobin from the Sea-Hemopure: clinical trials and current status.- Perftoran: History-Oxycyte-Hemoximer.- Transplantation.- Hemorrhagic Shock: HBOCs in Trauma.- Use of Oxygen.- Regulatory Update.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/neu
